Analysis By AlgoNomics Reveals That Anticalins(R) Intrinsically Have An Immunogenicity Level Comparable To The Wild-Type Human Lipocalin

Freising-Weihenstephan, Germany and Ghent, Belgium – December 13th, 2006 - Pieris AG, a biopharmaceutical company developing therapeutic products comprising of Anticalins®, a novel proprietary class of human binding proteins, and AlgoNomics NV, the immunogenicity screening company, today announced that AlgoNomics’ proprietary platform for T-cell epitope identification, Epibase®, revealed that Anticalins® intrinsically have an immunogenicity level comparable to the wild-type human lipocalin, as witnessed by a comparable number and promiscuity of the T-cell epitopes identified.